About
Alcresta Therapeutics is a biotechnology company based in Massachusetts that develops enzyme-based products to enhance nutritional care for patients with gastrointestinal disorders and rare diseases. The company primarily addresses pancreatic insufficiency, a condition that affects nutrient absorption in patients with conditions like cystic fibrosis and pancreatic cancer. Alcresta utilizes a proprietary technology platform to create solutions that improve the breakdown and absorption of essential fats, particularly omega-3 fatty acids. The flagship product, RELiZORB®, is an immobilized lipase cartridge designed for use with enteral feeding formulas. It enhances fat digestion and nutrient absorption for patients relying on tube feeding, optimizing their caloric intake. The next-generation RELiZORB device has received FDA 510(k) clearance and is set to launch in 2024. Alcresta is also developing products for patients with short bowel syndrome and premature infants in neonatal intensive care units, further expanding its focus on specialized nutritional support. The company is backed by prominent investors and led by CEO Daniel Orlando, who has extensive experience in therapeutic commercialization.
Technologies
Keywords
Company Information
-
Employees 83
-
Founded 2011
-
Annual Revenue $5000000
-
Total Funding $205279353
Location
2 Executive Park Drive, Newton, Massachusetts, United States, 02462
